Doug Hampton

Innovent and IASO Bio Updated Efficacy and Safety Clinical Data of Equecabtagene Autoleucel (BCMA CAR-T Cell Therapy) for Multiple Myeloma at the 2023 ASCO Annual Meeting USA – English APAC – English

by

ROCKVILLE, Md. and SUZHOU, China, June 5, 2023 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and other major diseases, and IASO Biotechnology (“IASO Bio”), a clinical-stage biopharmaceutical company engaged in discovering, developing, and manufacturing innovative … Read more

Transcenta Presents Updated Data of Osemitamab (TST001) in Combination with CAPOX as a First-Line Treatment of G/GEJ Cancer at 2023 ASCO Annual Meeting

by

SUZHOU, China, June 5, 2023 /PRNewswire/ — Transcenta Holding Limited (“Transcenta”) (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, has presented updated data of Cohort C from a phase I/IIa, multi-center study of Osemitamab (TST001) in combination with Capecitabine and Oxaliplatin (CAPOX) as a … Read more

Innovent Presents Phase 1 Clinical Data of IBI351 (KRASG12C Inhibitor) as Monotherapy for Metastatic Colorectal Cancer at the 2023 ASCO Annual Meeting

by

ROCKVILLE, Md. and SUZHOU, China, June 5, 2023 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and other major diseases, announced the preliminary data of IBI351 (GFH925, KRASG12C inhibitor) is presented at the 2023 American … Read more

Historic Actos RICO Class Action Against Big Pharma Could be Worth Billions

by

LOS ANGELES, June 5, 2023 /PRNewswire/ — A federal court unsealed an order that certified a national multi-billion dollar class action against Takeda Pharmaceutical Company and Eli Lilly and Company, alleging that the companies violated the civil Racketeer Influenced and Corrupt Organizations Act (RICO) by concealing the risk of Actos and bladder cancer. The Hon. … Read more

THE SCIENCE BEHIND OUR STRESS

by

LEARN HOW TO ACTIVELY REDUCE STRESS THROUGH STIMULATION OF THE VAGUS NERVE ROCKAWAY, N.J., June 5, 2023 /PRNewswire/ — BACKGROUND:Ask any American if they are currently living with stress and the answer would likely be a resounding YES. Everybody agrees that stress makes life less enjoyable, and it isn’t hard to see how it might … Read more

Waters Boosts Resolution and Triples Scan Speed of SELECT SERIES MRT for Metabolomics and MS Imaging

by

News Summary: New resolution enhancement mode (REM) for Waters’ multi-reflecting time-of-flight (MRT) mass spectrometer leads to greater specificity and higher sample throughput for metabolomics UPLC™-MS/MS and MS imaging studies. Waters’ MRT System is the only commercially available instrument capable of 300,000 full width half maximum (FWHM) resolution, a 3X faster scan rate and parts-per-billion mass … Read more

Medline optimizes leading Remedy Skin Care line

by

Updated packaging, clinical educational enhancements help clinicians elevate patient care delivery NORTHFIELD, Ill., June 5, 2023 /PRNewswire/ — Medline, the market leader in skin care, today announced a re-packaging initiative for its Remedy Skin Care line as part of the company’s commitment to making skin care more intuitive for clinicians. Attendees of this year’s WOCNext … Read more

Precigen Announces Positive Phase 1 Data for PRGN-3005 Autologous UltraCAR-T® Cells Manufactured Overnight for Infusion Next Day to Advanced Stage Platinum Resistant Ovarian Cancer Patients

by

“We are pleased with the results of the Phase 1 study which demonstrate a favorable safety profile for PRGN-3005 UltraCAR-T. Our UltraCAR-T therapies continue to be well-tolerated with no dose limiting toxicities across our clinical stage UltraCAR-T portfolio,” said Helen Sabzevari, PhD, President and CEO of Precigen. “At this early stage, we are encouraged that … Read more

Careismatic Brands, Inc. Acquires BALA Footwear

by

The performance shoe company joins Careismatic’s portfolio of innovative medical apparel brands. SANTA MONICA, Calif., June 5, 2023 /PRNewswire/ — Careismatic Brands, Inc., one of the world’s largest medical apparel companies, announced today that it has acquired BALA footwear, a nursing footwear company. BALA provides dynamic, high-performance shoes that enable healthcare workers to focus on … Read more

Hapbee Announces Closing of $710K Private Placement

by

VANCOUVER, BC, June 5, 2023 /PRNewswire/ – Hapbee Technologies, Inc. (TSXV: HAPB) (OTCQB: HAPBF) (FSE: HA1) (“Hapbee” or the “Company“), the digital wellness technology company is pleased to announce that it has completed a non-brokered private placement of units of the Company (“Units“) for aggregate gross proceeds to the Company of CAD$711,400 (the “Offering“). “This … Read more